Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

deuterated phenanthrene

A noncarcinogenic and structural analogue of polycyclic aromatic hydrocarbon (PAH), phenanthrene labeled with deuterium ([D10]Phe) with potential use in assessing an individual’s capacity for PAH metabolism by the diol epoxide pathway. Upon oral or inhalation administration, [D10]Phe is metabolized into the tetraol end product ([D10]PheT) via the diol epoxide pathway, and can be quantified in urine. [D10]PheT can be used as a biomarker to assess PAHs metabolic activation and may therefore determine an individual’s susceptibility to carcinogenicity upon PAH exposure.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	[D10] phenanthrene phenanthrene-D10
Abbreviation:	[D10]Phe

deuterated phenanthrene

Search NCI's Drug Dictionary